ABPI impressed by £220 million UK investment in life sciences tech
“A clear signal from government that the UK remains a great place for life-sciences” is how Mike Thompson, chief executive of the British Association of the Pharmaceutical Industry (ABPI), responded to news of a £220 million ($283 million) investment in new technology in the sector.
The UK’s Chancellor of the Exchequer Philip Hammond announced the funding for the life science and university sectors to help technology breakthroughs translate into commercial success, on Saturday.
This package is also aimed at ensuring disruptive businesses thrive in the UK. It includes £100 million of funding to extend and enhance the Biomedical Catalyst, which supports innovative UK life science companies to translate cutting-edge medical technologies into commercial success.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze